

Pyrazinamide Drug Resistance Patterns in Multi Drug Resistant *Mycobacterium tuberculosis* Isolates from India

K. Reena^{1, 2}, P. Kumar² and V. Shanthi^{1*}

¹Department of BioTechnology, School of Bio Sciences and Technology,
VIT University, Vellore, Tamil Nadu, India.

²National Tuberculosis Institute, Bangalore, India.

<https://doi.org/10.22207/JPAM.10.3.55>

(Received: 01 April 2016; accepted: 20 May 2016)

Inclusion of Pyrazinamide (PZA) in Tuberculosis (TB) chemotherapy has significantly shortened the treatment duration to 6 months. This is the only drug which is used in the treatment of both drug sensitive as well as Multi Drug Resistant (MDR) form of Tuberculosis. Although resistance to PZA is associated with poor treatment outcome Drug Susceptibility testing (DST) of PZA is not routinely performed due to technical difficulties in public health laboratories in India. The current study was undertaken to determine the proportion of PZA resistance in MDR and Non MDR TB and to propose the most feasible test that can be adopted for detecting PZA resistance. Sputum samples from 117 MDRTB suspects were tested for multi drug resistance using Line Probe Assay (LPA) and PZA DST was performed by MGIT and Pyrazinamidase enzyme activity was analyzed. 6.8% of the samples tested were MDR and almost 43% of them were resistant to Pyrazinamide. The *pncA* gene was sequenced for all isolates exhibiting phenotypic resistance. Nearly half of the MDRTB cases were resistant to PZA, indicating the need to customize the MDRTB regimen based on the PZADST result.

Keywords: Pyrazinamide drug susceptibility testing, Multi drug Resistant, *Mycobacterium tuberculosis*, LPA, Modified Wayne's assay.

Pyrazinamide is an important drug in anti TB treatment because of its high in vivo sterilizing activity against *Mycobacterium tuberculosis* particularly in acidic pH. Its combination with Rifampicin (R) and Isoniazid (H) in the standard TB treatment has reduced the duration of therapy from 12 to 6 months¹. PZA, like Isoniazid and Ethionamide, is a pro drug which must be converted into its active form, Pyrazinoic acid. The conversion into an active form is mediated by the enzyme called Pyrazinamidase (PZase) encoded by the *pncA* gene^{2, 3}. The literature evidences available clearly indicate that mutations in the *pncA* gene significantly affect the activity of PZase thus

conferring drug resistance^{4, 5, 6}. For instance, *Mycobacterium tuberculosis* isolates which were found to be resistant to Pyrazinamide had only minimal or no PZase activity. As, PZA is used for both first and second line anti TB treatment, understanding the prevalence of PZA resistance pattern is certainly helpful to improve the TB treatment regimen.

Many studies have demonstrated a high prevalence of PZA resistance among MDR-TB patients in different localities, ranging from 10% in Papua New Guinea and 25% in Turkey, to 49% in Thailand, 50% in Central Africa, 52% in South Africa, 53% in Japan, 55% in Taiwan, 77% in Pakistan and 85% in South Korea and in India⁷. As stated above, the prevalence of PZA resistance pattern in different countries ranges from 10-85% among MDR TB patients. Such variation may be due to widespread and indiscriminate use of PZA

* To whom all correspondence should be addressed.
Tel.: +91 9486536201; Fax: +91 4162243092;
E-mail : shanthi.v@vit.ac.in

in anti TB treatment regimen or overestimation of the proportion of PZA resistance due to false resistant results in the PZA DST ⁸.

Although the CLSI guidelines 2003 have recommended the use of BACTEC Mycobacterial Growth Indicator Tube (MGIT) 960 for PZA DST, the technique does not seem to yield reliable/reproducible results ^{9, 10, 11}. Results are dependent on size and quality of inoculums and the concentration of the PZA drug used in the DST ^{12, 13}. In addition, the culture medium has to be acidified which in turn affects the growth of *Mycobacterium tuberculosis* ¹⁴. Due to these technical challenges many laboratories refrain from performing the PZA DST.

MDRTB treatment comprises of 6 drugs for 6-9 months in the intensive phase and 4 drugs in the continuation phase of treatment. PZA is the only drug which is used both in the treatment of drug sensitive and drug resistant form of Tuberculosis. In previously treated tuberculosis cases, the prevalence of PZA resistance is expected to be high due to prior exposure to the drug. For such cases it would be unwise to include PZA in the MDRTB treatment regimen without knowing the in vitro drug susceptibility pattern. Moreover,

many clinicians expect a favorable MDRTB treatment outcome if the organism is susceptible to PZA. Hence, knowledge of the susceptibility pattern of PZA prior to initiation of MDRTB treatment is useful in guiding the clinician to determine the course of MDRTB treatment. Currently, under the Revised National TB Control Program (RNTCP), MDRTB treatment is initiated without PZA DST.

In light of the above situation, the present study was undertaken to determine the proportion of PZA drug resistance pattern in MDRTB suspects using the most reliable, phenotypic or Genotypic technique. It is believed that this data will be valuable to make policy decisions to test for PZA susceptibility before initiating MDRTB treatment.

MATERIALS AND METHODS

The study was performed at a public health reference laboratory for Tuberculosis. The laboratory caters to a population of about 10million for providing MDRTB diagnosis. For the current study, sputum samples received from a single tuberculosis centre over a period of month was only considered. A prospective study was



Fig. 1. Modified Wayne's test: 20mins after adding 1% Ferrous ammonium sulphate




Fig. 2. Correlation of PZA DST and MDRTB




Fig. 3. Lane description of samples 1- 20, L- 100bp ladder

undertaken on 117 sputum samples. All smear positive samples were subjected to the Genotype MTBDRplus assay (Hain Lifescience, Nehren, Germany) to detect multi drug resistance. Following this, all samples were cultured and PZA DST was set up using the modified Wayne's assay and MGIT. *pncA* gene was sequenced for all isolates exhibiting PZA resistance in vitro.

Sample digestion and decontamination

Sputum samples were processed in a Class II Bio safety cabinet in a BSL2 laboratory. Specimens were subjected to digestion and decontamination by the N-acetyl-L-cysteine-sodium hydroxide method¹⁵. Following centrifugation, the pellet was suspended in 1.0 ml of phosphate buffer (pH 6.8). A concentrated smear was prepared and examined using a fluorescence microscope and graded according to International Union Against Tuberculosis and Lung Disease (IUATLD) guidelines¹⁶. One loop full (5mm internal diameter) of the sediment was inoculated on to Lowenstein Jensen (LJ) Medium. The remaining pellet was taken up for LPA.

Culture on Lowenstein Jensen Medium

The inoculated LJ slopes were incubated at 37° C for a maximum of 8 weeks and they were checked weekly for appearance of rough, tough and buff colored colonies of *Mycobacterium tuberculosis*. The growth was confirmed to be *Mycobacterium tuberculosis* by an Immuno chromatic test (SD Bioline).

Geno Type MTBDR plus assay

LPA was performed directly on samples which were smear positive. Whereas for smear negative samples, LPA for performed after obtaining growth on LJ medium. The MTBDRplus was performed according to the manufacturer's instructions¹⁷. The test is based on DNA strip technology and has three steps: DNA extraction, multiplex polymerase chain reaction (PCR) amplification, and reverse hybridization. 500µl of the decontaminated sediment was used for DNA extraction. The organisms present in the sediment were heat killed by placing the tubes in a water bath which was set at 95° C. Following this, the cells were subjected to sonication and centrifugation. The supernatant containing DNA was carefully removed. The amplification and Hybridization procedure was performed as per the manufacturer's instructions. After hybridization the

nitrocellulose strips were removed and fixed on paper using a transparent cello tape. Each strip consists of 27 probes, including six controls (conjugate, amplification, *M. tuberculosis* complex, *rpoB*, *katG*, and *inhA* controls), eight *rpoB* wild-type (WT) and four mutant (MUT) probes. The eight *rpoB* WT's code for regions 506-509, 510-513, 513-517, 516-519, 518-522, 521-525, 526-529, 530-533. MUT 1 codes for D516V, MUT2A for H526Y, MUT2B for H526D and MUT3S531L. The *katG* WT1 codes for region 315 and MUT1 & 2 code for S315T1 and S315T2 respectively. The *inhA* has two wildtype probes WT1 & 2 which code for -15/-16 and -8. The strip consists of four mutations probes for *inhA*. MUT1 codes for C15T, MUT2 codes for A16G, MUT3A codes for T8C and MUT3B codes for T8A. Results were interpreted according to the manufacturer's instructions and reported to the concerned authorities for appropriate treatment initiation.

Modified Wayne's Enzymatic Assay

The procedure for performing modified Wayne's enzymatic assay was obtained from Singh et al., 2007. Heavy growth of *Mycobacterium tuberculosis* isolates was required for performing the test. The assay medium consisted of Modified Middlebrook 7H9 broth, 400¼g of PZA drug powder and 1.5% of agar agar. Initially the medium was autoclaved at 121 °C for 20 minutes and then allowed to cool to 60° C. Subsequently, the growth supplement was added to the medium. 4ml of the molten medium was then poured into Mc Cartney bottles and kept upright to solidify. After solidification, the entire batch of media was placed in the incubator at 37° C for sterility check. Change in color of the uninoculated medium indicates contamination in the medium. Subsequently, the medium was inoculated by stabbing it 3-4 times with 2-3 loopfulls of *Mycobacterium tuberculosis* growth. The inoculated tubes were incubated at 37° C for 4 days. The tubes were tested for the PZase enzyme activity on the fourth day by the following technique. 1ml of freshly prepared 1% ferrous ammonium sulphate was added to the medium. The tubes were observed for 20 mins. Pink to red color band in the sub surface of the medium indicates the presence of active PZase enzyme and is able to hydrolyze the PZA drug into Pyrazinoic acid. The isolate was declared sensitive to PZA. In case of absence of a pink color band within 20

```

gi|H37Rv|gb|M.tb  GTCGGTCATGTTTCGCGATCGTCGCGGCGTCATGGACCCTATATCTGTGGCTGCCGCGTCG 60
gi|R1|gb|SRL      GTCGGTCATGTTTCGCGATCGTCGCGGCGTCATGGACCCTATATCTGTGGCTGCCGCGTCG
gi|R4|gb|SRL      GTCGGTCATGTTTCGCGATCGTCGCGGCGTCATGGACCCTATATCTGTGGCTGCCGCGTCG
gi|R2|gb|SRL      GTCGGTCATGTTTCGCGATCGTCGCGGCGTCATGGACCCTATATCTGTGGCTGCCGCGTCG
gi|R3|gb|SRL      GTCGGTCATGTTTCGCGATCGTCGCGGCGTCATGGACCCTATATCTGTGGCTGCCGCGTCG
gi|R5|gb|SRL      GTCGGTCATGTTTCGCGATCGTCGCGGCGTCATGGACCCTATATCTGTGGCTGCCGCGTCG
gi|R6|gb|SRL      GTCGGTCATGTTTCGCGATCGTCGCGGCGTCATGGACCCTATATCTGTGGCTGCCGCGTCG
gi|R7|gb|SRL      GTCGGTCATGTTTCGCGATCGTCGCGGCGTCATGGACCCTATATCTGTGGCTGCCGCGTCG
gi|R8|gb|SRL      GTCGGTCATGTTTCGCGATCGTCGCGGCGTCATGGACCCTATATCTGTGGCTGCCGCGTCG
gi|R9|gb|SRL      GTCGGTCATGTTTCGCGATCGTCGCGGCGTCATGGACCCTATATCTGTGGCTGCCGCGTCG
gi|R10|gb|SRL     GTCGGTCATGTTTCGCGATCGTCGCGGCGTCATGGACCCTATATCTGTGGCTGCCGCGTCG
gi|R11|gb|south   GTCGGTCATGTTTCGCGATCGTCGCGGCGTCATGGACCCTATATCTGTGGCTGCCGCGTCG
gi|R12|gb|OR      GTCGGTCATGTTTCGCGATCGTCGCGGCGTCATGGACCCTATATCTGTGGCTGCCGCGTCG
gi|R13|gb|OR      GTCGGTCATGTTTCGCGATCGTCGCGGCGTCATGGACCCTATATCTGTGGCTGCCGCGTCG
gi|R14|gb|OR      GTCGGTCATGTTTCGCGATCGTCGCGGCGTCATGGACCCTATATCTGTGGCTGCCGCGTCG
gi|R15|gb|SMS     GTCGGTCATGTTTCGCGATCGTCGCGGCGTCATGGACCCTATATCTGTGGCTGCCGCGTCG
gi|R16|gb|SMS     GTCGGTCATGTTTCGCGATCGTCGCGGCGTCATGGACCCTATATCTGTGGCTGCCGCGTCG
                    *****
                    *****

gi|H37Rv|gb|M.tb  GTAGAAGAACTGCCCGGCGAGTCGCCCAGACGTATGGTGGACGTATGCGGGCGTTGATC 120
gi|R1|gb|SRL      -----GGCCCGT--CCAGGACGGATCG-----
gi|R4|gb|SRL      GTAGGCA-AACTGCCCGGCGAGTCGCCCAGACGTATGGTGGACGTATGCGGGCGTTGATC
gi|R2|gb|SRL      GTAGGAA-GACTGCCCGGCGAGTCGCCCAGACGTATGGTGGACGTATGCGGGCGTTGATC
gi|R3|gb|SRL      GTAGGCA-AACTGCCCGGCGAGTCGCCCAGACGTATGGTGGACGTATGCGGGCGTTGATC
gi|R5|gb|SRL      GTAGGCA-AACTGCCCGGCGAGTCGCCCAGACGTATGGTGGACGTATGCGGGCGTTGATC
gi|R6|gb|SRL      GTAGGCA-AACTGCCCGGCGAGTCGCCCAGACGTATGGTGGACGTATGCGGGCGTTGATC
gi|R7|gb|SRL      GTAGGCA-AACTGCCCGGCGAGTCGCCCAGACGTATGGTGGACGTATGCGGGCGTTGATC
gi|R8|gb|SRL      GTAGGCA-AACTGCCCGGCGAGTCGCCCAGACGTATGGTGGACGTATGCGGGCGTTGATC
gi|R9|gb|SRL      GTAGGCA-AACTGCCCGGCGAGTCGCCCAGACGTATGGTGGACGTATGCGGGCGTTGATC
gi|R10|gb|SRL     GTAGGCA-AACTGCCCGGCGAGTCGCCCAGACGTATGGTGGACGTATGCGGGCGTTGATC
gi|R11|gb|south   GTAGGCA-AACTGCCCGGCGAGTCGCCCAGACGTATGGTGGACGTATGCGGGCGTTGATC
gi|R12|gb|OR      GTAGGCA-AACTGCCCGGCGAGTCGCCCAGACGTATGGTGGACGTATGCGGGCGTTGATC
gi|R13|gb|OR      GTAGGCA-AACTGCCCGGCGAGTCGCCCAGACGTATGGTGGACGTATGCGGGCGTTGATC
gi|R14|gb|OR      GTAGGCA-AACTGCCCGGCGAGTCGCCCAGACGTATGGTGGACGTATGCGGGCGTTGATC
gi|R15|gb|SMS     GTAGGCA-AACTGCCCGGCGAGTCGCCCAGACGTATGGTGGACGTATGCGGGCGTTGATC
gi|R16|gb|SMS     GTAGGCA-AACTGCCCGGCGAGTCGCCCAGACGTATGGTGGACGTATGCGGGCGTTGATC
                    *****

gi|H37Rv|gb|M.tb  ATCGTCGACGTGCAGAACGACTTCTGCGAGGGTGGCTCGCTGGCGGTAACCGGTGGCGCC 180
gi|R1|gb|SRL      -TCGTGCAC-----GGC-----GGCCAGGGTGGCCCCGTTGCGATGA-----CGG
gi|R4|gb|SRL      ATCGTCGACGTGCAGAACGACTTCTGCGAGGGTGGCTCGCTGGCGGTAACCGGTGGCGCC
gi|R2|gb|SRL      ATCGTCGACGTGCAGAACGACTTCTGCGAGGGTGGCTCGCTGGCGGTAACCGGTGGCGCC
gi|R3|gb|SRL      ATCGTCGACGTGCAGAACGACTTCTGCGAGGGTGGCTCGCTGGCGGTAACCGGTGGCGCC
gi|R5|gb|SRL      ATCGTCGACGTGCAGAACGACTTCTGCGAGGGTGGCTCGCTGGCGGTAACCGGTGGCGCC
gi|R6|gb|SRL      ATCGTCGACGTGCAGAACGACTTCTGCGAGGGTGGCTCGCTGGCGGTAACCGGTGGCGCC
gi|R7|gb|SRL      ATCGTCGACGTGCAGAACGACTTCTGCGAGGGTGGCTCGCTGGCGGTAACCGGTGGCGCC
gi|R8|gb|SRL      ATCGTCGACGTGCAGAACGACTTCTGCGAGGGTGGCTCGCTGGCGGTAACCGGTGGCGCC
gi|R9|gb|SRL      ATCGTCGACGTGCAGAACGACTTCTGCGAGGGTGGCTCGCTGGCGGTAACCGGTGGCGCC
gi|R10|gb|SRL     ATCGTCGACGTGCAGAACGACTTCTGCGAGGGTGGCTCGCTGGCGGTAACCGGTGGCGCC
gi|R12|gb|OR      ATCGTCGACGTGCAGAACGACTTCTGCGAGGGTGGCTCGCTGGCGGTAACCGGTGGCGCC
gi|R13|gb|OR      ATCGTCGACGTGCAGAACGACTTCTGCGAGGGTGGCTCGCTGGCGGTAACCGGTGGCGCC
gi|R14|gb|OR      ATCGTCGACGTGCAGAACGACTTCTGCGAGGGTGGCTCGCTGGCGGTAACCGGTGGCGCC
gi|R15|gb|SMS     ATCGTCGACGTGCAGAACGACTTCTGCGAGGGTGGCTCGCTGGCGGTAACCGGTGGCGCC
gi|R16|gb|SMS     ATCGTCGACGTGCAGAACGACTTCTGCGAGGGTGGCTCGCTGGCGGTAACCGGTGGCGCC
                    **** *
                    *

gi|H37Rv|gb|M.tb  GCGCTGGCCCCGCGCCATCAGCGACTACCTGGCCGAA-- 216
gi|R1|gb|SRL      TAAATGTCGAACAGGATCAGCGACTACCTCCGCCGAAA
gi|R4|gb|SRL      GCGCTGGCCCCGCGCCATCAGCGACTCTTGGCAAAA---
gi|R2|gb|SRL      GCGCTGGCCCCGCGCCATCAGCGACTACCTGGCCGAA--
gi|R3|gb|SRL      GCGCTGGCCCCGCGCCATCAGCGACTACCTGGCCGAA--
gi|R5|gb|SRL      GCGCTGGCCCCGCGCCATCAGCGACTACCTGGCCGAA--
gi|R6|gb|SRL      GCGCTGGCCCCGCGCCATCAGCGACTACCTGGCCGAA--
gi|R7|gb|SRL      GCGCTGGCCCCGCGCCATCAGCGACTACCTGGCCGAA--
gi|R8|gb|SRL      GCGCTGGCCCCGCGCCATCAGCGACTACCTGGCCGAA--
gi|R9|gb|SRL      GCGCTGGCCCCGCGCCATCAGCGACTACCTGGCCGAA--
gi|R10|gb|SRL     GCGCTGGCCCCGCGCCATCAGCGACTACCTGGCCGAA--
gi|R11|gb|south   GCGCTGGCCCCGCGCCATCAGCGACTACCTGGCCGAA--
gi|R12|gb|OR      GCGCTGGCCCCGCGCCATCAGCGACTACCTGGCCGAAA-
gi|R13|gb|OR      GCGCTGGCCCCGCGCCATCAGCGACTACCTGGCCGAA--
gi|R14|gb|OR      GCGCTGGCCCCGCGCCATCAGCGACTACCTGGCCGAA--
gi|R15|gb|SMS     GCGCTGGCCCCGCGCCATCAGCGACTACCTGGCCGAA--
gi|R16|gb|SMS     GCGCTGGCCCCGCGCCATCAGCGACTACCTGGCCGAA--
                    *** *
                    *****

```

Fig. 4. CLUSTAL O(1.2.1) multiple sequence alignment






Fig. 5. ClustalW2 Phylogeny

mins, the tubes were placed at 4⁰ C and observed after 4 hrs. The result was declared to be sensitive if a pink color band appeared in the medium and resistant if there was no development of pink color.

PZA Drug susceptibility testing by MGIT 960

The growth obtained from LJ medium was sub cultured onto a MGIT (Becton Dickinson, Sparks, MD) tube. A freshly positive MGIT tube was used for the PZA test. The media for performing the PZA drug susceptibility testing consists of the BACTEC MGIT 960 PZA (Becton Dickinson, Sparks, MD) medium tube (containing 7ml of Modified Middlebrook 7H9broth), the PZA drug kit (consisting of the lyophilized PZA drug, 20,000 1/4g) and growth supplement. The lyophilized drug was reconstituted with 2.5ml of sterile distilled water. As per the manufacturer's instructions, the test was set up in a two AST Set Carrier where the








Fig. 6. Blast x analysis to determine change in protein

Growth Control and PZA tubes were placed in sequence. The test has a 21 day protocol and the machine declares results as “Resistant” or “Susceptible” (MGIT procedure manual 2006).

Sequencing of *pncA* gene

The *pncA* gene of 20 *Mycobacterium tuberculosis* isolates was sequenced along with H37Rv strain of *M.tb*. Isolates were grown in liquid culture medium and DNA was extracted using standardized methods. The DNA was amplified using *pncA* primers (P1 5'GTC GGTCATGTTTCGCGATCG, and P2-5'TCGGCCAGGTAGTCGCTGAT)¹⁸. The PCR

reaction mixture contained DNA (100ng) 1 μ l, Forward primer (100ng μ l) 2 μ l, Reverse primer (100ng μ l) 2 μ l, dNTPs (2.5mM each) 2 μ l, 10x Taq pol assay buffer 5 μ l, Taq Polymerase (3u μ l) 0.5 μ l and Water to obtain a final reaction volume of 50 μ l. The PCR cycle parameters were set at 94°C for 5min, 94°C for 1 min, 57°C for 1min, 72°C for 1min and 72°C for 7min. The amplified PCR product was run on 2% agarose gel and an amplicon size of 222bp was obtained. The purified PCR product was sequenced using Applied biosystems 3500 (Chromous biotech, Bangalore). The chromatograms obtained were analyzed using the

Table 1. Reason for testing vs MDR status.

Category of patient	Reason for testing	Number of MDR (mono RIF)	Number of Non MDR(mono INH)	Total number of cases
1	Failure	1	6	7
2	Retreatment case smear positive at 4 months of treatment	1	3	4
3	Contact of known MDRTB case	0	3	3
4	S+ at diagnosis, re-treatment case	4(1)	52 (4)	61
5	Any follow up S+	0	15 (2)	17
6	S- at diagnosis, re-treatment case	1	8	9
7	HIV TB case	0	7	7
8	Private referral	0	9	9

Table 3. Correlation between MDR status, PZA drug susceptibility testing, PZase enzyme activity and nucleotide changes in the *pncA* gene.

MDR Status	PZA DST	PZase enzyme activity	<i>pncA</i> mutation nucleotide change
MDR (3)	R	R	A65G (3), A66C (2), G67A(2), 67 Deletion(1), 68deletion(2), A69G(1), A206C(1), C207T (1), C208T(1), T209G(1), G211C(1), C212A(1), C213A(1), C214A(1)
MDR(4)	S	S	A65G(3), C66A(1), A66C(2), 67 Deletion(3)
Non MDR (1)	S	S	A65G, C66A, 67deletion
Non MDR (1)	S	R	A65G, C66A, 67deletion
Mono INH (5)	S	S	A65G(5), C66A(2), A66C(3), 67deletion(5)
Mono INH(1)	R	R	T21C, C22A,C24T, G26A, C27G, G28C, T29A, C30G, A31C,T32C, C38G, A40G, T43C, C44T, T45G, G48A, G49C, C50A, T51G,G52C, G55T, C56T, G57C, T58A, 61-77 deletion, 84- 85 deletion, 100-119deletion, 131-145deletion A168G, C170G, C171G, 172-179 deletion, G181T, C182A, G183A, C184aA G187tT C189G, C190A, G191A, G193A, C194G, C195G, G210C,G211C,G212C, G214AA215F
Mono Rif (1)	R	R	A65G,A66C,G67A, 68 deletion

DNA Baser- chromatogram explorer lite v4.0.0. The nucleotide sequence was analysed using and clustalW.

RESULTS

Of the 117 samples 2 were smear negative and 115 were smear positive. Smear negative samples were cultured and LPA was performed on culture isolates. In all 117 samples were subjected to LPA. 109 (93%) of the samples were Non MDR while 8 (6.8%) were MDR. Of the 109 Non MDR's, 6 were Mono Isoniazid resistant and 103 were sensitive to both Rifampicin & Isoniazid. Further, PZA drug resistance was detected using two methods. The performance of Modified Wayne's assay Fig.1 was evaluated against PZA DST by MGIT which was considered as the reference standard. The specificity of the test was 100% and sensitivity was 99%. The positive predictive value and negative predictive values were 86% & 100% respectively. The Modified Wayne's assay had an overall efficiency of 99% when compared with the MGIT. The PZA DST results were correlated with their MDR status and are presented in Fig.2. The reason for suspecting MDRTB in the samples referred for testing was tabulated and is found in Table.1. 52% of the samples belonged to patients who were previously treated smear positive. Of the 8 MDR's, 7 were male patients and 1 was a female patient. The MDR patients were grouped according to their age and reason for testing. This data is presented in Table.2 to find out if there was a particular age group in which the proportion of MDR's was higher. The most common mutation was the S531L which was present in 5 out of 8 MDR strains. Presence of all rpoB WT bands with a MUT 2A band was detected in one strain. 7 out of 8 MDR strains had a missing KatG WT, indicating low level Isoniazid resistance. Almost 50% (of the MDR isolates showed phenotypic resistance to PZA, however only 2% of the Non MDR's showed phenotypic resistance to PZA.

Sequencing analysis

All the 6 isolates exhibiting phenotypic resistance to PZA and 10 isolates which were PZA sensitive in phenotypic tests was taken up for pncA gene sequencing. Amplicon size of 222bp was sequenced (Fig.3). The nucleotide sequence obtained was analyzed using clustalW 2 Fig.4. The

phylogeny of the samples tested was also analyzed and is presented in Fig.5. All the genetic sequences were subjected to Blast x analysis to determine if they coded for Pyrazinamidase. Results of the Blast x analysis of all the 16 isolates which were sequenced are presented in Fig.6. The correlation between MDR status, PZA drug susceptibility testing, PZase enzyme activity and nucleotide changes in the pncA gene are presented in Table.3. Of the 6 isolates which showed phenotypic resistance 3 isolates had mutations and did not code for the PZase enzyme. There was 100% agreement between phenotypic and genotypic results for isolates which were susceptible to PZA and had a functional PZase enzyme.

DISCUSSION

The prevalence of MDR among new TB cases is around 2-5% and among previously treated cases is estimated to be about 12% as per the national data ¹⁹. However, the percentage of MDR among MDRTB suspects that were tested was around 6.8% which is similar to National data reported in 2015 ²⁰. Considering the fact that programmatic management of drug resistant TB services has been in place since 2012, the prevalence of MDR seems to have decreased. This indicates that the program has been successful in identifying and treating MDRTB and has been able to cut the chain of transmission. In our study, 50% of the samples were from sputum smear positive previously treated cases. Multi drug resistance was not detected in any of the contacts of an MDRTB case. Contrary to the common expectation, that the percentage of MDRTB is higher in the private sector or in HIV patients coinfecting with TB, we did not find any MDRTB case among these two populations. Proportion of MDR's was the highest in male patients in the 26-35 age groups. RpoB S531L was the most common mutation observed in our study which appears as a band in MUT3 of LPA is similar to previously published data from India ²¹. Low level resistance to isoniazid due to the absence of WT band in the KatG region and presence of MUT1 was found to be common. There was good correlation between the MGIT DST results and the modified Wayne's enzymatic assay in our study. Comparative studies conducted in India also showed similar results. However, these

studies have used the radiometric BACTEC460 TB system which is an older method^{22, 23}. Although the culture systems used by us and by others are slightly different, the critical concentration of PZA was the same (100µgm/ml).

Almost 50% of the MDRTB cases were found to be resistant to Pyrazinamide and did not possess Pyrazinamidase activity. The *pncA* gene sequencing showed nucleotide substitutions and insertions. Contrary to the findings in other studies, the mutations were not dispersed throughout the *pncA* gene in our study^{24, 25}. Except for two isolates all the others showed mutations in 65, 67 and 68. 80% of the isolates showed deletion of nucleotide at position 67 of the *pncA* gene. Substitution of AàC was observed in half of the isolates while the other half had C àA. One of the isolates showed nucleotide deletion in 61-77, 84-85, 100-119, 131-145, 172-179 and produced an uncharacterized protein with a resistant phenotypic result. Further, some researchers have shown some degree of conservation of *pncA* mutations between 3-17, 67-76, 132-142 in the pyrazinamidase protein^{25, 26}. These three regions are important in the formation of the active site of the enzyme²⁷. The strains in our study had mutations in 2 of these conserved areas in which mutations were very common. 12% of our strains had mutations (substitutions, deletions) in regions which were not previously described. Our study has shown 87% correlation between phenotypic and genotypic results and has shown that 50% of MDRTB cases were resistant to PZA. As proposed by Ying Zhang et al., 2012, it would be prudent to classify MDRTB as PZA resistant or sensitive before initiating MDRTB treatment. This kind of pre classification of MDRTB patient will help the clinicians in forecasting patient treatment outcomes. Further, clinical studies are required to take this forward.

ACKNOWLEDGEMENTS

The authors express deep sense of gratitude to the Management of Vellore Institute of Technology and National Tuberculosis Institute for all the support, assistance and constant encouragements to carry out this work.

REFERENCES

1. Stoffels K, Mathys V, Fauville-Dufaux M, Wintjens R, Bifani P. Systematic Analysis of Pyrazinamide-Resistant Spontaneous Mutants and Clinical Isolates of *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother.*, 2012; **56**: 5186-5193.
2. DeBarber AE, Mdluli K, Bosman M, Bekker LG, Barry CE. Ethionamide activation and sensitivity in multidrug-resistant *Mycobacterium tuberculosis*. *Proc Natl Acad Sci U S A.*, 2000; **97**: 9677-9682.
3. Hirano K, Takahashi M, Kazumi Y, Fukasawa Y, Abe C. Mutation in *pncA* is a major mechanism of pyrazinamide resistance in *Mycobacterium tuberculosis*. *Tuber Lung Dis.*, 1997; **78**: 117-122.
4. Sreevatsan S, Pan X, Zhang Y, Kreiswirth BN, Musser JM. Mutations Associated with Pyrazinamide Resistance in *pncA* of *Mycobacterium tuberculosis* Complex Organisms. *Antimicrob Agents Chemother.*, 1997; **41**: 636-640.
5. Mestdagh M, Fonteyne PA, Realini L, Rossau R, Jannes G, Mijs W, De Smet KA, Portaels F, Van den Eeckhout E. Relationship between Pyrazinamide Resistance, Loss of Pyrazinamidase Activity, and Mutations in the *pncA* Locus in Multidrug-Resistant Clinical Isolates of *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother.*, 1999; **43**: 2317-2319.
6. Jureen P, Werngren J, Toro JC, Hoffner S. Pyrazinamide Resistance and *pncA* Gene Mutations in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother.*, 2008; **52**: 1852-1854.
7. Ying Zhang, Kwok Chiu Chang, Chi-Chiu Leung, Wing Wai Yew, Brigitte Gicquel, Dorothy Fallows, Gilla Kaplan, Richard E Chaisson, Wenhong Zhang. 'ZS -MDR-TB' versus 'ZR-MDR-TB': improving treatment of MDR-TB by identifying pyrazinamide susceptibility. *Emerging Microbes and Infections.*, 2012; **1**(5): 1-4.
8. Zhang Y, Mitchison D. (). The curious characteristics of pyrazinamide: a review. *Int J Tuberc Lung Dis.*, 2003; **7**: 6-21.
9. Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F. Potential for Erroneous Results Indicating Resistance When Using the Bactec MGIT 960 System for Testing Susceptibility of *Mycobacterium tuberculosis* to Pyrazinamide. *J Clin Microbiol.*, 2010; **48**: 300-301.

10. A, Hirano K, Hamasaki S, Abe C. Evaluation of BACTEC MGIT 960 PZA medium for susceptibility testing of *Mycobacterium tuberculosis* to pyrazinamide (PZA): compared with the results of pyrazinamidase assay and Kypkuto PZA test. *Diagn Microbiol Infect Dis.*, 2002; **44**: 347–352.
11. Pfyffer GE, Palicova F, Rüschi-Gerdes S. Testing of susceptibility of *Mycobacterium tuberculosis* to pyrazinamide with the nonradiometric BACTEC MGIT 960 System. *J Clin Microbiol.*, 2002; **40**: 1670–1674.
12. Scarparo C, Ricordi P, Ruggiero G, Piccoli P. Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility of *Mycobacterium tuberculosis* to pyrazinamide, streptomycin, isoniazid, rifampin, and ethambutol and comparison with the radiometric BACTEC 460TB method. *J Clin Microbiol.*, 2004; **42**: 1109–1114.
13. Zhang Y, Permar S, Sun Z. Conditions that may affect the results of susceptibility testing of *Mycobacterium tuberculosis* to pyrazinamide. *J. Med. Microbiol.*, 2002; **51**: 42–49.
14. Heifets L, Lindholm-Levy P. Pyrazinamide sterilizing activity *in vitro* against semidormant *Mycobacterium tuberculosis* bacterial populations. *Am Rev Respir Dis.*, 1992; **145**: 1223–1225.
15. Kent PT, Kubica GP. Public health mycobacteriology: a guide for the level III laboratory. Atlanta, GA: Centers for Disease Control. 1985.
16. Enarson DA, Rieder HL, Arnadottir T, Trebucq A. Management of tuberculosis: a guide for low income countries. Paris, France. International Union Against Tuberculosis and Lung Disease. 2000
17. Hain Lifescience, GmbH. GenoType MTBDR plus, version 1.0 Nehren, Germany. Available from: http://www.hain-lifescience.com/pdf/304xx_pbl.pdf. 2007
18. P. Parthiban, S.S. Prabhu, M. Muthuraj, T. Elavazhagan and S. Manupriya. Characterization of PncA Gene Responsible for Pyrazinamidase Enzyme in *Mycobacterium tuberculosis* Clinical Isolate. *American-Eurasian Journal of Scientific Research.*, 2009; **4**: 198–203.
19. Revised National Tuberculosis Control Program, Guidelines for Programmatic Management of Drug Resistant Tuberculosis .2012.
20. TB India. Revised National Tuberculosis Control Program, Annual status report. Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare. 2015
21. Raj N. Yadav, Binit K. Singh, Surendra K. Sharma, Rohini Sharma, Manish Soneja, Vishnubhatla Sreenivas, Vithal P. Myneedu, Mahmud Hanif, Ashok Kumar, Kuldeep S. Sachdeva, Chinnambedu N. Paramasivan, Balasangameshwara Vollepore, Rahul Thakur, Neeraj Raizada, Suresh K. Arora, Sanjeev Sinha. Comparative Evaluation of GenoType MTBDRplus Line Probe Assay with Solid Culture Method in Early Diagnosis of Multidrug Resistant Tuberculosis (MDR-TB) at a Tertiary Care Centre in India. *PLOS One.*, 2013; **8**: 200–215
22. A. Krishnamurthy, D Almeida, C Rodrigues, A Mehta. Comparison of Pyrazinamide drug susceptibility of *Mycobacterium tuberculosis* by radiometric BACTEC and Enzymatic Pyrazinamidase assay. *Indian Journal of Medical Microbiology.*, 2004; **3**: 166–168.
23. Babita Sharma, Nita Pal, Bharti Malhotra, Leela Vyas & Suman Rishi. Comparison of MGIT 960 & pyrazinamidase activity assay for pyrazinamide susceptibility testing of *Mycobacterium tuberculosis*. *Indian Journal of Medical Research.*, 2010; **132**: 72–76.
24. Scorpio, A.; Lindholm-Levy, P.; Heifets, L. Characterization of pncA mutations in Pyrazinamide resistant *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.*, 1997; **41**: 540–543.
25. Hirano, K.; Takahashi, M.; Kazumi, Y.; Fukasawa, Y.; Abe, C. Mutation in pncA is a major mechanism of Pyrazinamide resistance in *Mycobacterium tuberculosis*. *Tubercle. Lung Dis.* 1998; **78**: 117–122.
26. Hou, L.; Osei-Hyiaman, D. Zhang, Z. Molecular characterization of pncA gene mutations in *Mycobacterium tuberculosis* clinical isolates from China. *Epidemiol. Infect.*, 2000; **124**: 227–232.
27. Barco1, P.; Cardoso, R.F.; Hirata1, R.D.C.; Leite, C.Q.F.; Pandolfi, J.R. ; Sato, D.N.; Shikama, M.L.; Fiúza de Melo, F.; Mamizuka1, E.M.; Campanerut, P.A.Z.; Hirata, M.H. pncA mutations in pyrazinamide-resistant *Mycobacterium tuberculosis* clinical isolates from the southeast region of Brazil. *J. Antimicrob. Chemother.*, 2006; **58**: 930–935.

© The Author(s) 2016. **Open Access.** This article is distributed under the terms of the [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.